Role of intestinal microbiota in transplantation outcomes

Publication date: Available online 22 October 2015 Source:Best Practice & Research Clinical Haematology Author(s): Ying Taur, Rob Jenq, Carles Ubeda, Marcel van den Brink, Eric G. Pamer While allogeneic hematopoietic stem cell transplantations have a curative potential, infections and graft-versus-host disease remain significant problems. The intestinal microbiota can influence responses to cancer chemotherapy and the role of the microbiota in affecting allogeneic hematopoietic stem cell transplantation outcomes is increasingly appreciated. The following paper discusses the most recent developments in this area.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research

Related Links:

AbstractAcute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (alloSCT) remains a major therapeutic challenge. While patients with longer remission after initial alloSCT are recommended to receive cell therapy (CT) such as 2ndalloSCT or donor lymphocyte infusion (DLI), survival for patients who relapse within 6  months of alloSCT has been dismal. We evaluated the outcomes of AML relapse after alloSCT to assess the impact of different treatments on long-term survival. One hundred and seventy-two patients with AML underwent alloSCT at the Penn State Cancer Institute from January 2014 to August 2019....
Source: Annals of Hematology - Category: Hematology Source Type: research
CONCLUSIONS: The available evidence on the benefits and harms of CAR T-cell therapy for people with r/r DLBCL is limited, mainly because of the absence of comparative clinical trials. The results we present should be regarded in light of this limitation and conclusions should be drawn very carefully. Due to the uncertainty in the current evidence, a large number of ongoing investigations and a risk of substantial and potentially life-threatening complications requiring supplementary treatment, it is critical to continue evaluating the evidence on this new therapy.PMID:34515338 | DOI:10.1002/14651858.CD013365.pub2
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research
Eva Lion Despite the advent of novel therapies, acute myeloid leukemia (AML) remains associated with a grim prognosis. This is exemplified by 5-year overall survival rates not exceeding 30%. Even with frontline high-intensity chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the majority of patients with AML will relapse. For these patients, treatment options are few, and novel therapies are urgently needed. Adoptive T-cell therapies represent an attractive therapeutic avenue due to the intrinsic ability of T lymphocytes to recognize tumor cells with high specificity and efficiency. In par...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
AbstractOnco-nephrology is a recent and evolving medical subspecialty devoted to the care of patients with kidney disease and unique kidney-related complications in the context of cancer and its treatments, recognizing that management of kidney disease as well as the cancer itself will improve survival and quality of life. While this area has received much attention in the adult medicine sphere, similar emphasis in the pediatric realm has not yet been realized. As in adults, kidney involvement in children with cancer extends beyond the time of initial diagnosis and treatment. Many interventions, such as chemotherapy, stem ...
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
Up-regulation of inhibitory receptors, such as programmed death-1 (PD-1), is an integral component of tumor immune escape, chemotherapy resistance, and disease progression, features which have been identified in acute myeloid leukemia (AML).1 –4 Since the approval of pembrolizumab for metastatic melanoma in September 2014, we have seen an immunologic renaissance unfold with transformative changes in in the management of a growing list of cancers. As of April 2021, seven anti-PD-1/PD-L1 monoclonal antibodies have been approved across 19 different hematologic and solid malignancies, as well as two tissue-agnostic conditions (e.g.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
J Cell Mol Med. 2021 Aug 25. doi: 10.1111/jcmm.16870. Online ahead of print.ABSTRACTIt has been demonstrated that neural precursor cell expressed developmentally downregulated protein (NEDD) plays crucial roles in tumorigenesis and may serve as potential biomarkers in cancer diagnosis and prognosis. However, few studies systematically investigated the expression of NEDD family members in acute myeloid leukaemia (AML). We systemically determined the expression of NEDD family members in AML and determined their clinical significance. We identified that NEDD9 expression was the only member among NEDD family which was signific...
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
Stem Cell Res Ther. 2021 Aug 20;12(1):465. doi: 10.1186/s13287-021-02420-8.ABSTRACTAcute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable hematological malignancy that affects the myeloid cell progenies and challenges patients of all ages but mostly occurs in adults. Although several therapies are available including chemotherapy, allogeneic hematopoietic stem cell transplantation (alloHSCT), and receptor-antagonist drugs, the 5-year survival of patients is quietly disappointing, less than 30%. alloHSCT is the major curative approach for AML with promising results but the treatment has severe adver...
Source: Cell Research - Category: Cytology Authors: Source Type: research
In this study, we reported a case of refractory diffuse large B-cell lymphoma with cutaneous involvement that achieved complete remission for more than 4 years with epigenetic regulation of chidamide in combination with chemotherapy and autologous hematopoietic stem cell transplantation including a pretreatment regimen containing chidamide.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
Br J Dermatol. 2021 Aug;185(2):e36-e67. doi: 10.1111/bjd.20528.ABSTRACTLinked Article: Vanden Oever et al. Br J Dermatol 2021; 185:380-390. Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disorder. Patients with RDEB experience severe painful blistering and skin fragility due to separation of two layers of the skin: the dermis and epidermis. This occurs because type VII collagen (C7) is deficient or absent in the skin. C7 is a major component responsible for tethering the epidermis to the dermis. The skin heals with disfiguring scarring, and patients are at risk of secondary infection and an aggressive ...
Source: The British Journal of Dermatology - Category: Dermatology Source Type: research
In conclusion, cancer survivors, especially older individuals, demonstrate greater odds of and accelerated functional decline, suggesting that cancer and/or its treatment may alter aging trajectories. Linking Particulate Air Pollution and Dementia in a Small Region of the US https://www.fightaging.org/archives/2021/08/linking-particulate-air-pollution-and-dementia-in-a-small-region-of-the-us/ It is fairly settled that evident particulate air pollution, such as daily exposure to smoke from wood-fueled cooking fires, has a strongly detrimental effect on long-term health. The mechanisms involved are inflamm...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Stem Cell Therapy | Stem Cells | Transplants